ArticleJournal of neurology, neurosurgery, and psychiatry1999
Successful treatment of IgM paraproteinaemic neuropathy with fludarabine.
Article in Journal of neurology, neurosurgery, and psychiatry, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 102 citations in OpenAlex.
- Decrease in Serum Anti-MAG Autoantibodies Is Associated With Therapy Response in Patients With Anti-MAG Neuropathy: Retrospective Study.Neurology(R) neuroimmunology & neuroinflammation · 2022Pooled it
- Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies.The Cochrane database of systematic reviews · 2016Pooled it
- Correlation of Streptococcus agalactiae concentration on immune system and effective dose of inactivated vaccine for Chitralada 3 strain Nile tilapia (Oreochromis niloticus) in Thailand.BMC veterinary research · 2023Article
- Article
- Immunoglobulin M Monoclonal Gammopathies of Clinical Significance.Frontiers in oncology · 2022Review
- Immunoglobulin M Paraproteinaemias.Cancers · 2020Review
- Advances in the diagnosis, immunopathogenesis and therapies of IgM-anti-MAG antibody-mediated neuropathies.Therapeutic advances in neurological disorders · 2018Review
- Monoclonal Gammopathy-Associated Peripheral Neuropathy: Diagnosis and Management.Mayo Clinic proceedings · 2017Review
- Warfarin improves neuropathy in monoclonal gammopathy of undetermined significance.BMJ case reports · 2016Article
- Paraproteinemic neuropathy: a practical review.BMC neurology · 2016Review
- Treatment of chronic inflammatory demyelinating polyneuropathy.Current neurology and neuroscience reports · 2015Review
- An update on monoclonal gammopathy and neuropathy.Current neurology and neuroscience reports · 2012Review
- Pathogenesis and Treatment of Anti-MAG Neuropathy.Current treatment options in neurology · 2010Article
- Disease associations with monoclonal gammopathy of undetermined significance: a population-based study of 17,398 patients.Mayo Clinic proceedings · 2009Article
- Inflammatory demyelinating neuropathies and neuropathies associated with monoclonal gammopathies: treatment update.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2008Review
- Current therapies for neuromuscular manifestations of paraneoplastic syndromes.Current neurology and neuroscience reports · 2006Article
- Inflammatory neuropathies: an update on evaluation and treatment.Current rheumatology reports · 2005Review
- Treatment of dys-immune neuropathies.Journal of neurology · 2005Review
- Paraproteinemic Neuropathy.Current treatment options in neurology · 2001Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo evaluate the response of four patients with IgM paraproteinaemic neuropathy to a novel therapy-pulsed intravenous fludarabine.
backgroundThe peripheral neuropathy associated with IgM paraproteinaemia usually runs a chronic, slowly progressive course which may eventually cause severe disability. Treatment with conventional immunosuppressive regimens has been unsatisfactory. Fludarabine is a novel purine analogue which has recently been shown to be effective in low grade lymphoid malignancies.
methodsFour patients were treated with IgM paraproteinaemic neuropathy with intravenous pulses of fludarabine. Two of the four patients had antibodies to MAG and characteristic widely spaced myelin on nerve biopsy and a third had characteristic widely spaced myelin only. The fourth had an endoneurial lymphocytic infiltrate on nerve biopsy and a diagnosis of Waldenström's macroglobulinaemia.
resultsIn all cases subjective and objective clinical improvement occurred associated with a significant fall in the IgM paraprotein concentration in three cases. Neurophysiological parameters improved in the three patients examined. The treatment was well tolerated. All patients developed mild, reversible lymphopenia and 50% mild generalised myelosuppression, but there were no febrile episodes.
conclusionFludarabine should be considered as a possible treatment for patients with IgM MGUS paraproteinaemic neuropathy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.